
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Feb 12, 2026 02:31 am UTC| Business Health Governance
Novocure (NASDAQ: NVCR) stock soared more than 30% in extended trading Wednesday after the U.S. Food and Drug Administration (FDA) approved its Optune Pax device for the treatment of locally advanced pancreatic cancer. The...

FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Feb 11, 2026 01:46 am UTC| Governance Business Health
The U.S. Food and Drug Administration (FDA) has declined to review Modernas approval application for its experimental influenza vaccine, mRNA-1010, a decision that sent the companys shares down about 8% in extended...

Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Feb 11, 2026 01:30 am UTC| Business Health Governance
Moderna Inc. (NASDAQ: MRNA) shares declined sharply in after-hours trading on Tuesday after the biotechnology company disclosed that the U.S. Food and Drug Administration (FDA) has declined to review its influenza vaccine...

Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Feb 09, 2026 05:22 am UTC| Business Health
Innovent Biologics Inc (HK:1801) shares surged in Hong Kong trading on Monday after the Chinese biotech company announced a major new partnership with longtime U.S. collaborator Eli Lilly and Company (NYSE:LLY), focused on...

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Feb 08, 2026 00:59 am UTC| Business Health Governance
Hims Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a warning from the U.S. Food and Drug Administration, which said it would take action against the...

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Feb 08, 2026 00:42 am UTC| Health Business
Pharmaceutical and telehealth companies are spending millions of dollars on celebrity-driven Super Bowl ads as competition heats up in the fast-growing weight-loss drug market. Brands behind GLP-1 weight-loss medications,...

FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Feb 07, 2026 03:05 am UTC| Governance Health Business
The U.S. Food and Drug Administration (FDA) announced on Friday that it will take enforcement action against telehealth provider Hims Hers over its $49 weight-loss pill, escalating scrutiny of compounded GLP-1 drugs sold...